# Forbion Capital Partners: portfolio, investments and team

> Forbion Capital Partners is a private equity based in Netherlands. 134 investments on record, 23 in the last 12 months, latest Oct 2026.

Source: https://millionrounds.com/fund/forbion-capital-partners (Millionrounds; every figure on the page links to its filing or article)

Netherlands · [Investor](https://millionrounds.com/investors)

# Forbion Capital Partners

Last cheque observed Oct 2026; 134 cheques on record.

Email

Deploying now New fund $2.6B, Oct 2026 Private equity

Seed Series A Series B Ehealth Connected Health Health

Follow Forbion Capital Partners and see its new cheques in your feed. [Start following](https://millionrounds.com/login?join=1&why=follow&next=%2Ffund%2Fforbion-capital-partners)

Deploying now

**92%** of best year **23** **cheques in 12 months**, 134 on record

Since the last cheque **16** days **00** hrs **00** min **00** sec

Median round **$88M** Cheque size, as they say **$100K – $5.0M** Rounds led **10 of 134** Sole investor **10 rounds** Exits **8 from the portfolio** Mostly in **United States, 51%**

Pitch Forbion Capital Partners

## Forbion Capital Partners highlights

- 01 23 cheques in the last 12 months
- 02 Mostly Series A and Series B: 68% of its rounds
- 03 Sole investor in 10 rounds, median $17M
- 04 8 exits from the portfolio

## What they do

> Forbion is a global venture capital firm dedicated to advancing groundbreaking biotech innovations and other sustainable solutions. From their own website

- **Type:** Private equity (from a list, unverified)
- **Cheque size:** $100K – $5.0M as they say
- **Stages:** Seed Series A Series B Growth Pre-IPO
- **Sectors:** Ehealth Connected Health Health
- **Based in:** Naarden, Netherlands
- **Cold pitches:** Not stated

## The record

Every round we can evidence, newest first **134 appearances**

- **2026** 16 rounds
- **Oct** **[OMass Therapeutics](https://millionrounds.com/company/omass-therapeutics)** Series C · GB · Jefferson Life Sciences **$310M** *Led*
- **Sept** **[Solstice Oncology](https://millionrounds.com/company/solstice-oncology)** Series A · US **$225M** With 2 others
- **Sept** **[Sling Therapeutics](https://millionrounds.com/company/sling-therapeutics)** Series C · US **$123M** With 1 other
- **Sept** **[Orbis Medicines](https://millionrounds.com/company/orbis-medicines)** Venture · DK **$94M** With 4 others
- **Sept** **[Navigator Medicines](https://millionrounds.com/company/navigator-medicines)** Venture · US **$10M** With 1 other
- **Jul** **[Dyne Therapeutics](https://millionrounds.com/company/dyne-therapeutics)** US **$375M** With 3 others
- **Jun** **[RQ Bio](https://millionrounds.com/company/rq-bio)** Series A · GB · Frazier Life Sciences **$115M** With 7 others
- **Jun** **[cAMPfield Therapeutics, Inc.](https://millionrounds.com/company/campfield-therapeutics-inc)** Series A · US · Frazier Life Sciences **$180M** With 7 others
- **Jun** **[Memento Medicines](https://millionrounds.com/company/memento-medicines)** Series A · GB · Avego Management **$93M** *Led*
- **May** **[CellCentric](https://millionrounds.com/company/cellcentric)** Growth · Ventureburn **$220M** With 6 others
- **Mar** **[Tropic Biosciences](https://millionrounds.com/company/tropic-biosciences)** Series C · GB **$105M** With 4 others
- **Mar** **[Mestag Therapeutics](https://millionrounds.com/company/mestag-therapeutics)** Venture · GB **$40M** With 3 others
- **Feb** **[Altesa](https://millionrounds.com/company/altesa)** Series B · US **$75M** With 2 others
- **Feb** **[Slate Medicines](https://millionrounds.com/company/slate-medicines)** Series A · US **$130M** With 2 others
- **Jan** **[Corsera Health](https://millionrounds.com/company/corsera-health)** Series A · US **$80M** Sole investor
- **Jan** **[Beacon Therapeutics](https://millionrounds.com/company/beacon-therapeutics)** Series C · US **$75M** With 4 others
- **2025** 22 rounds
- **Dec** **[Sidera Bio](https://millionrounds.com/company/sidera-bio)** Series A · DK **$109M** With 3 others
- **Dec** **[Crescent Biopharma](https://millionrounds.com/company/crescent-biopharma)** US **$185M** With 4 others
- **Dec** **[Protego Biopharma](https://millionrounds.com/company/protego-biopharma)** Series B · US · Firms' own news pages **$130M** *Led*
- **Dec** **[Dyne Therapeutics](https://millionrounds.com/company/dyne-therapeutics)** US **$403M** With 3 others
- **Nov** **[AAVantgarde Bio](https://millionrounds.com/company/aavantgarde-bio)** Series B · IT **$141M** With 3 others
- **Nov** **[Braveheart Bio](https://millionrounds.com/company/braveheart-bio)** Series A · US **$185M** With 2 others
- **Nov** **[Gate Bioscience](https://millionrounds.com/company/gate-bioscience)** Series B · US **$65M** With 5 others
- **Oct** **[PACT](https://millionrounds.com/company/pact)** Series A · GB **$21M** With 2 others
- **Oct** **[Elevara Medicine](https://millionrounds.com/company/elevara-medicine)** Series A · GB **$70M** With 1 other
- **Oct** **[Expedition Therapeutics](https://millionrounds.com/company/expedition-therapeutics)** Series A · US **$165M** With 3 others
- **Sept** **[Genomines](https://millionrounds.com/company/genomines)** Series A · FR · DTCF DeepTech & Climate Fonds **$45M** With 7 others
- **Sept** **[Sparrow Pharmaceuticals](https://millionrounds.com/company/sparrow-pharmaceuticals)** Series B · US **$95M** With 2 others
- **Jul** **[MapLight Therapeutics](https://millionrounds.com/company/maplight-therapeutics)** Series D · US · Avego Management **$373M** *Led*
- **Jun** **[Mosanna Therapeutics](https://millionrounds.com/company/mosanna-therapeutics)** Series A · CH · Silicon Canals **$80M** With 9 others
- **May** **[CellCentric](https://millionrounds.com/company/cellcentric)** Series C · GB · Avego Management **$120M** With 3 others
- **May** **[Azafaros](https://millionrounds.com/company/azafaros)** Series B · NL · Seroba Life Sciences **$147M** *Led*
- **Apr** **[eeden](https://millionrounds.com/company/eeden)** Series A · DE · Silicon Canals **$21M** *Led*
- **Apr** **[Granite Bio](https://millionrounds.com/company/granite-bio)** Series B · US · Silicon Canals **$70M** *Led*
- **Apr** **[AIRNA](https://millionrounds.com/company/airna)** Series B · US · LifeLink Ventures **$155M** *Led*
- **Feb** **[Genetix Biotherapeutics Inc.](https://millionrounds.com/company/genetix-biotherapeutics-inc)** Venture · US **Undisclosed** With 4 others
- **Jan** **[Verdiva Bio](https://millionrounds.com/company/verdiva-bio)** Series A · GB **$411M** With 4 others
- **Jan** **[Orbis Medicines](https://millionrounds.com/company/orbis-medicines)** Series A · DK · Silicon Canals **$94M** With 7 others
- **2024** 18 rounds
- **Dec** **[Citryll](https://millionrounds.com/company/citryll)** Series B · NL · Silicon Canals **$90M** *Led*
- **Dec** **[Noema Pharma](https://millionrounds.com/company/noema-pharma)** Series B · CH **$147M** With 3 others

An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.

## The team

Named by the firm itself, on a filing, its Form ADV or its company registration **2 named**

MA **Martien Adrianus Van Osch** Managing Member i Form ADV

VV **Vincent Van Houten** Chief Financial Officer i Form ADV

We also hold **30** people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.

## What the register says

From the firm's own filings with the SEC, which it must file accurately by law

**$6.9B** gross assets of its funds Oct 2026

**Exempt** reporting adviser venture or small private funds

- **Legal name:** FCPM III Services B.v.
- **SEC number:** CRD 162925

Who backs their funds

## 1 LP on record in Forbion Capital Partners's funds

- **Committed:** $853M
- **Funds:** 4
- **Vintages:** 2023 to 2024

The institutions that put money into its funds, which the firm then invests in companies. Source: the pension's own report, latest Mar 2026.

- [**California Public Employees' Retirement System (CalPERS)** 4 funds *$853M*](https://millionrounds.com/fund/california-public-employees) Fund Vintage Committed Forbion Growth Opportunities Fund III Co?peratief U.A. 2024 $384M Forbion Ventures Fund VII Co?peratief U.A. 2024 $272M Forbion Ventures Fund VI Cooperatief U.A. 2023 $180M Forbion Growth Opportunities Fund II Cooperatief U.A. 2023 $17M

## What they claim to have backed

From their own portfolio page (on their website)

**0** of 1 we have independently watched raise

Made with Friend Studio

Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded.

## Exits from the portfolio

Companies it backed that were later bought or listed **8 in all**

**[Dezima Pharma](https://millionrounds.com/company/dezima-pharma)** Bought by [Amgen](https://millionrounds.com/fund/amgen) **$300M** Sept 2015

**[PneumRx](https://millionrounds.com/company/pneumrx)** Bought by [BTG](https://millionrounds.com/fund/btg) **$475M** Dec 2014

**[Santaris Pharma](https://millionrounds.com/company/santaris-pharma)** Bought by Roche **$450M** Aug 2014

**[CircuLite](https://millionrounds.com/company/circulite)** Bought by HeartWare International **$30M** Dec 2013

**[bluebird bio](https://millionrounds.com/company/bluebird-bio)** Listed **$101M** Jun 2013

**[Pathway Medical Technologies](https://millionrounds.com/company/pathway-medical-technologies)** Bought by MEDRAD **Undisclosed** Sept 2011

**[BioVex](https://millionrounds.com/company/biovex)** Bought by [Amgen](https://millionrounds.com/fund/amgen) **$1.0B** Jan 2011

**[Fovea Pharmaceuticals](https://millionrounds.com/company/fovea-pharmaceuticals)** Bought by [Sanofi Aventis](https://millionrounds.com/fund/sanofi) **Undisclosed** Oct 2009

An exit counts when it came after the firm's first round in the company. From historical deal records.

New fund on file

**$2.6B**

raised in Oct 2026

From its SEC filing, not a journalist: a firm that has just raised has money to deploy.

## The cheque

Seed Series A Series B

Median round joined **$88M** the round, not its cheque Alone, median **$17M**

Led 10 of 134 rounds **7%**

- **Said size:** $100K – $5.0M
- **Sole investor:** 10 rounds
- **Last cheque:** Oct 2026
- **Exits:** 8 from the portfolio

Rounds by stage said on their site

- Series A said *43*
- Series B said *38*
- Series C *15*
- Venture *12*
- Series D *11*
- Seed said *-*
- Growth said *-*

Cheques by month Led Joined

Nov 2023 Oct 2026

Often in the room with

- [RA Capital Management](https://millionrounds.com/fund/ra-capital-management) 21
- [OrbiMed](https://millionrounds.com/fund/orbimed) 11
- [Novo Holdings](https://millionrounds.com/fund/novo-ventures) 10
- [Sofinnova Partners](https://millionrounds.com/fund/sofinnova-partners) 9
- [Omnes](https://millionrounds.com/fund/omnes-capital) 8
- [Crédit Agricole](https://millionrounds.com/fund/credit-agricole) 7

**Pitching Forbion Capital Partners?** Put them on your fundraising board with this record on the card, and follow them to hear when they write a new cheque.

Add to your CRM *→*

## Who they invest alongside

The investors most often in the same rounds as Forbion Capital Partners. A count of rooms they were both in, not a relationship either has claimed.

[**RA Capital Management** Private equity **21** rounds together](https://millionrounds.com/fund/ra-capital-management)[**OrbiMed** Private equity **11** rounds together](https://millionrounds.com/fund/orbimed)[**Novo Holdings** VC firm **10** rounds together](https://millionrounds.com/fund/novo-ventures)[**Sofinnova Partners** VC firm **9** rounds together](https://millionrounds.com/fund/sofinnova-partners)[**Omnes** VC firm **8** rounds together](https://millionrounds.com/fund/omnes-capital)[**Crédit Agricole** VC firm **7** rounds together](https://millionrounds.com/fund/credit-agricole)[**Omega Funds** VC firm **7** rounds together](https://millionrounds.com/fund/omega-funds)[**Sanofi** Investment firm **7** rounds together](https://millionrounds.com/fund/sanofi)[**Atlas Venture** VC firm **6** rounds together](https://millionrounds.com/fund/atlas-venture)[**Eli Lilly** Corporate VC **6** rounds together](https://millionrounds.com/fund/eli-lilly)[**Novartis** VC firm **6** rounds together](https://millionrounds.com/fund/novartis)[**Perceptive Advisors** Asset manager **6** rounds together](https://millionrounds.com/fund/perceptive-advisors)

## Recently backed

The latest companies Forbion Capital Partners put money into.

[**OMass Therapeutics** $310M · Oct 2026](https://millionrounds.com/company/omass-therapeutics)[**Solstice Oncology** $225M · Sept 2026](https://millionrounds.com/company/solstice-oncology)[**Sling Therapeutics** $123M · Sept 2026](https://millionrounds.com/company/sling-therapeutics)[**Orbis Medicines** $94M · Sept 2026](https://millionrounds.com/company/orbis-medicines)[**Dyne Therapeutics** $375M · Jul 2026](https://millionrounds.com/company/dyne-therapeutics)[**CellCentric** $220M · May 2026](https://millionrounds.com/company/cellcentric)

## Quick answers about Forbion Capital Partners

### What does Forbion Capital Partners invest in?

Forbion Capital Partners invests most often at Series A and Series B (68% of the rounds on record), in sectors such as Ehealth, Connected Health and Health.

### How active is Forbion Capital Partners?

134 investments on record, 23 of them in the last 12 months, and it led 10. The most recent was in Oct 2026.

### What has Forbion Capital Partners invested in recently?

Its most recent investments on record: OMass Therapeutics (Series C, Oct 2026), Solstice Oncology (Series A, Sept 2026) and Sling Therapeutics (Series C, Sept 2026).

### How big are Forbion Capital Partners's cheques?

The median round it joins is $88M. It says it writes cheques of $100K to $5.0M.

### Does Forbion Capital Partners lead rounds?

Sometimes: it led 10 of its 134 investments on record (7%).

### Where does Forbion Capital Partners invest?

Most of the companies it backs are in the United States (51%), the United Kingdom (23%) and Denmark (8%).

### Is Forbion Capital Partners investing now?

Yes: it is actively investing, with 23 investments in the last 12 months.

### Who does Forbion Capital Partners invest alongside?

Most often RA Capital Management (21 rounds together), OrbiMed (11 rounds together) and Novo Holdings (10 rounds together).

## Raising now?

Find the investors who back rounds like yours, and keep every conversation on one fundraising board.

Find similar investorsOpen your CRM

Built from the rounds we watched, its filings and its own website, refreshed every night. [How we count](https://millionrounds.com/methodology) · [Report a correction](https://millionrounds.com/corrections?slug=forbion-capital-partners) · [Is this your firm? Claim it](https://millionrounds.com/claim?org=forbion-capital-partners)